Última revisão: 22 Mai 2021
Última atualização: 14 Nov 2018

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • história de asma, rinite alérgica ou sinusite
  • fraqueza ou dormência focal
  • obstrução ou secreção nasal, ou dor facial
  • púrpura palpável e petéquias
  • sibilo
  • hemoptise
  • nódulos cutâneos

Outros fatores diagnósticos

  • uso de determinados medicamentos
  • fadiga, artralgias, mialgias
  • dispneia ou tosse
  • dor abdominal
  • deficits sensoriais ou motores
  • taquipneia
  • estertores
  • edema periférico
  • ortopneia
  • refluxo hepatojugular

Fatores de risco

  • história de asma, rinite alérgica ou sinusite
  • uso de determinados medicamentos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • Hemograma completo com diferencial
  • anticorpos anticitoplasma de neutrófilo (ANCA) séricos
  • proteína C-reativa sérica
  • velocidade de hemossedimentação
  • ureia e creatinina séricas
  • urinálise
  • teste de função pulmonar
  • radiografia torácica
  • ecocardiograma

Investigações a serem consideradas

  • citometria de fluxo de sangue periférico
  • testes moleculares para mutação FIP1L1/PDGFR alfa
  • imunoglobulina E (IgE) sérica
  • IgE e IgG séricas específicas para Aspergillus fumigatus
  • coprocultura para ovos e parasitas
  • Sorologia para Toxocara
  • tomografia computadorizada (TC) do tórax
  • eletromiografia
  • broncoscopia com lavagem broncoalveolar (LBA)
  • biópsia do tecido afetado
  • ultrassonografia de membro inferior
  • Angiotomografia
  • biópsia da medula óssea
  • nível da tiopurina metiltransferase
  • teste de vírus da imunodeficiência humana (HIV)

Novos exames

  • ressonância nuclear magnética (RNM) cardíaca
  • eotaxina-3

Algoritmo de tratamento

Colaboradores

Assistant Professor

Division of Pulmonary and Critical Care Medicine

Mayo Clinic

Rochester

MN

Declarações

KK is an author of a number of references cited in this topic and has developed educational material on Churg-Strauss syndrome for First Consult (Elsevier). KK has undertaken contractual research for GlaxoSmithKline (utilizing mepolizumab and sirukumab in asthma trials), but received no personal financial gain for this work.

Dr Karina Keogh would like to gratefully acknowledge Dr Garvan Kane, a previous contributor to this topic. GK is an author of a number of references cited in this topic.

RevisoresVER TUDO

Professor of Rheumatology

NIHR Musculoskeletal Biomedical Research Unit

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science

University of Oxford

Oxford

UK

Declarações

RL has organisational financial interests with funds received for consultation and training on disease assessment in vasculitis for GlaxoSmithKline, Nordic, and Chemocentryx. RL has received personal funds for lectures on vasculitis from Roche and Nippon Kayaku. RL is an author of a reference cited in this topic.

Clinical Senior Lecturer in Renal Medicine

Centre for Translational Inflammation Research

University of Birmingham Research Laboratories

Queen Elizabeth Hospital Birmingham

Birmingham

UK

Declarações

MDM has been a paid consultant for Sphere Medical Ltd, and has received research grants and funding from GlaxoSmithKline and Novartis.

Assistant Professor of Medicine

Division of Rheumatology

Johns Hopkins University School of Medicine

Co-Director

Johns Hopkins Vasculitis Center

Baltimore

MD

Declarações

PS declares that he has no competing interests.

Professor of Clinical Rheumatology

Institute of Cellular Medicine

Newcastle University

Newcastle upon Tyne

Honorary Consultant Rheumatologist

The James Cook University Hospital

Middlesbrough

UK

Declarações

JVL is consultant for Roche, the manufacturer of rituximab, and has received speaker fees and reimbursements for attending several conferences.

Associate Professor and Director

Division of Rheumatology

University of Arkansas for Medical Sciences

Little Rock

AR

Declarações

RAO declares that he has no competing interests.

O uso deste conteúdo está sujeito ao nosso aviso legal